Compound Planning Inc. Buys 94 Shares of McKesson Corporation $MCK

Compound Planning Inc. grew its stake in shares of McKesson Corporation (NYSE:MCK) by 8.8% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,166 shares of the company’s stock after purchasing an additional 94 shares during the period. Compound Planning Inc.’s holdings in McKesson were worth $785,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in MCK. Brighton Jones LLC grew its stake in McKesson by 46.3% in the fourth quarter. Brighton Jones LLC now owns 2,523 shares of the company’s stock valued at $1,438,000 after acquiring an additional 798 shares during the period. Integrated Wealth Concepts LLC lifted its holdings in shares of McKesson by 3.3% in the 4th quarter. Integrated Wealth Concepts LLC now owns 4,192 shares of the company’s stock worth $2,389,000 after purchasing an additional 135 shares in the last quarter. Capital Analysts LLC grew its position in McKesson by 38.0% in the 4th quarter. Capital Analysts LLC now owns 392 shares of the company’s stock valued at $224,000 after purchasing an additional 108 shares during the period. Coldstream Capital Management Inc. increased its stake in McKesson by 3.7% during the 4th quarter. Coldstream Capital Management Inc. now owns 3,414 shares of the company’s stock valued at $1,945,000 after purchasing an additional 122 shares in the last quarter. Finally, Johnson Financial Group Inc. acquired a new position in McKesson during the fourth quarter worth $76,000. 85.07% of the stock is currently owned by institutional investors and hedge funds.

McKesson Stock Performance

NYSE:MCK opened at $687.7050 on Monday. McKesson Corporation has a 52 week low of $464.42 and a 52 week high of $737.89. The firm has a 50-day moving average price of $706.69 and a two-hundred day moving average price of $685.75. The firm has a market cap of $85.54 billion, a price-to-earnings ratio of 27.42, a price-to-earnings-growth ratio of 1.37 and a beta of 0.50.

McKesson (NYSE:MCK) last announced its earnings results on Wednesday, August 6th. The company reported $8.26 earnings per share for the quarter, missing analysts’ consensus estimates of $8.33 by ($0.07). The business had revenue of $97.83 billion during the quarter, compared to analysts’ expectations of $95.93 billion. McKesson had a negative return on equity of 196.66% and a net margin of 0.84%.McKesson’s quarterly revenue was up 23.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $7.88 EPS. As a group, sell-side analysts forecast that McKesson Corporation will post 32.77 earnings per share for the current year.

McKesson Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 1st. Shareholders of record on Tuesday, September 2nd will be paid a $0.82 dividend. This is a boost from McKesson’s previous quarterly dividend of $0.71. The ex-dividend date is Tuesday, September 2nd. This represents a $3.28 dividend on an annualized basis and a yield of 0.5%. McKesson’s dividend payout ratio is currently 11.32%.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. Morgan Stanley reaffirmed an “overweight” rating and issued a $810.00 price objective (up from $770.00) on shares of McKesson in a research note on Wednesday, July 16th. Wall Street Zen cut shares of McKesson from a “strong-buy” rating to a “buy” rating in a research report on Sunday, July 13th. Cowen reissued a “buy” rating on shares of McKesson in a report on Thursday, August 7th. Bank of America increased their price objective on McKesson from $755.00 to $800.00 and gave the stock a “buy” rating in a research note on Friday, May 9th. Finally, Evercore ISI raised their target price on McKesson from $760.00 to $800.00 and gave the company an “outperform” rating in a report on Wednesday, July 9th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $725.10.

Insider Activity

In related news, CFO Britt J. Vitalone sold 1,878 shares of the stock in a transaction dated Wednesday, May 28th. The shares were sold at an average price of $717.91, for a total transaction of $1,348,234.98. Following the completion of the transaction, the chief financial officer owned 14,028 shares in the company, valued at approximately $10,070,841.48. This represents a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Brian S. Tyler sold 11,930 shares of the firm’s stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $677.76, for a total transaction of $8,085,676.80. Following the sale, the chief executive officer owned 15,942 shares of the company’s stock, valued at $10,804,849.92. This trade represents a 42.80% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 56,620 shares of company stock worth $39,712,388. 0.08% of the stock is owned by insiders.

McKesson Company Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.